Codagenix Expands Senior Management Team With Three New Appointments
New Hires Bolster Codagenix s Operations, Regulatory Affairs and Clinical Trial Management
News provided by
Share this article
Share this article
NEW YORK, March 17, 2021 /PRNewswire/ Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the expansion of its senior management team with three new appointments. Lisa Runco, Ph.D., has been named Director of Operations. Additionally, Sally Yang, M.S., R.A.C. has been appointed Associate Director of Regulatory Affairs, and Lasmy Tea, M.S., M.P.H., has been named Associate Director of Clinical Project Management.